| Literature DB >> 34494875 |
Dolla Karam Sarkis1, Benoît Doublet2, Myriam Mikhayel2,1, Sébastien O Leclercq2,3.
Abstract
The objective of the present study was to determine genomic characteristics of expanded-spectrum cephalosporin (ESC)-resistant Escherichia coli spreading in healthy broilers in Lebanon in 2018. Rectal swabs (n = 280) from 56 farms were screened for the presence of ESC-resistant E. coli isolates. Antimicrobial susceptibility and extended-spectrum β-lactamase (ESBL)/AmpC production were determined by the disk diffusion method. Whole-genome sequencing (WGS) of 102 representative isolates of E. coli was performed to determine their phylogenetic diversity, serotypes, sequence types (ST), acquired resistance genes, and virulence-associated genes. Fifty-two out of 56 farms housed broilers carrying ESC-resistant E. coli isolates. These farms had large and recurrent antimicrobial practices, using, for some of them, critically important antibiotics for prophylactic and therapeutic purposes. Among the 102 sequenced multidrug-resistant (MDR) E. coli isolates, the proportion of ESBL, plasmid-mediated AmpC β-lactamase (pAmpC) producers, and ESBL/pAmpC coproducers was 60%, 27.6%, and 12.4%, respectively. The most prevalent ESBL/pAmpC genes were blaCMY-2, blaCTX-M-3, blaCTX-M-15, blaCTX-M-27, and blaCTX-M-14b (n = 42, n = 31, n =15, n = 9, and n = 7, respectively). These ESBL/pAmpC producers were distributed in different STs, most being well-known avian-associated and sometimes pathogenic STs (ST-10, ST-48, ST-93, ST-115, ST-117, and ST-457). Phylogenetic single nucleotide polymorphism (SNP) analysis confirmed their genetic diversity and wide dispersion across the Lebanese territory. Most isolates were also resistant to ciprofloxacin (101/102 with 3 QRDR mutations), and 19/102 isolates from 11 unrelated STs also carried the mobile resistance gene mcr-1. This survey illustrates the alarming prevalence of MDR E. coli resistant to medically important antibiotics in broilers in Lebanon. This advocates the need for surveillance programs of antimicrobial resistance in Lebanon and the reduction of excessive use of antibiotics to limit the spread of MDR E. coli in food-producing animals. IMPORTANCE Poultry production is a main contributor of the global trend of antimicrobial resistance arising from food-producing animals worldwide. In Lebanon, inappropriate use of antibiotics is frequent in chickens for prophylactic reasons and to improve productivity, resulting in an alarming prevalence of extended-spectrum β-lactamase (ESBL)/AmpC-producing Escherichia coli, also resistant to other medically important antibiotics (i.e., colistin and ciprofloxacin). Their complex genomic epidemiology highlighted by an important genetic diversity suggests that these resistance determinants are largely spreading in enteric bacteria in Lebanese poultry. Further molecular surveillance is needed to understand the country-specific epidemiology of ESBL/AmpC and mcr-1 genes in Lebanese poultry production. In addition, decisive interventions are urgently needed in order to ban the use of critically important antibiotics for human medicine in food-producing animals and limit the spread of antibiotic resistance in Lebanon.Entities:
Keywords: CMY-2; CTX-M-3; antibiotic usage; multidrug resistance; poultry
Mesh:
Substances:
Year: 2021 PMID: 34494875 PMCID: PMC8557922 DOI: 10.1128/Spectrum.00025-21
Source DB: PubMed Journal: Microbiol Spectr ISSN: 2165-0497
Antibiotic treatments in the sampled farms
| Farm ID | Region | Administered antibiotics | Antibiotic treatment duration (days) | Reasons for antibiotic usage |
|---|---|---|---|---|
| A1 | Akkar | Amoxicillin, ampicillin, cephalexin, ciprofloxacin, colistin, doxycycline, gentamicin, trimethoprim/sulfamethoxazole | 6 | Prevention and cure |
| A2 | Akkar | Amoxicillin, ampicillin, cephalexin, ciprofloxacin, colistin, doxycycline, gentamicin | 6 | Prevention and cure |
| A3 | Akkar | Amoxicillin, ampicillin, cephalexin, ciprofloxacin, colistin, doxycycline, florfenicol, tilmicosin | 3 | Prevention and cure |
| A4 | Akkar | Ciprofloxacin, colistin, doxycycline, florfenicol, gentamicin | 6 | Prevention and cure |
| A5 | Akkar | Colistin, doxycycline, tilmicosin | 6 | Prevention and cure |
| A6 | Akkar | Ciprofloxacin, colistin, doxycycline, tilmicosin | 5 | Prevention and cure |
| Bb1 | Baalbeck | Colistin, doxycycline, florfenicol, gentamicin | 10 | Prevention and cure |
| Bb2 | Baalbeck | Colistin, doxycycline, florfenicol, gentamicin | 10 | Prevention and cure |
| Bb3 | Baalbeck | Ciprofloxacin, colistin, doxycycline, trimethoprim/sulfamethoxazole | 30 | Prevention and cure |
| Bb4 | Baalbeck | Ciprofloxacin, colistin, doxycycline, trimethoprim/sulfamethoxazole | 30 | Prevention and cure |
| B1 | Beqaa | Colistin, doxycycline, florfenicol, gentamicin, tilmicosin | 10 | Prevention and cure |
| B2 | Beqaa | Ciprofloxacin, doxycycline, gentamicin | 10 | Prevention and cure |
| B3 | Beqaa | Amoxicillin, doxycycline, gentamicin | 5 | Prevention and cure |
| B4 | Beqaa | Ciprofloxacin, doxycycline | 10 | Prevention and cure |
| B5 | Beqaa | Doxycycline | 5 | Prevention and cure |
| B6 | Beqaa | Amoxicillin, ampicillin, cephalexin, ciprofloxacin, colistin, doxycycline, gentamicin, trimethoprim/sulfamethoxazole | 10 | Prevention and cure |
| B7 | Beqaa | Ciprofloxacin, doxycycline, gentamicin, trimethoprim/sulfamethoxazole | 5 | Prevention and cure |
| B8 | Beqaa | Doxycycline | 5 | Prevention and cure |
| M1 | Mount Lebanon | Doxycycline, florfenicol, gentamicin, tetracycline, trimethoprim/sulfamethoxazole | 5 | Prevention and cure |
| M2 | Mount Lebanon | Ciprofloxacin, doxycycline, gentamicin | 3 | Prevention and cure |
| M3 | Mount Lebanon | Ciprofloxacin, doxycycline | 5 | Prevention and cure |
| M4 | Mount Lebanon | Ciprofloxacin, doxycycline, gentamicin | 5 | Prevention and cure |
| M5 | Mount Lebanon | Ciprofloxacin, tilmicosin | 5 | Prevention and cure |
| M6 | Mount Lebanon | Cephalexin, ciprofloxacin, colistin, doxycycline, gentamicin, trimethoprim/sulfamethoxazole | 3 | Prevention and cure |
| M7 | Mount Lebanon | NA | NA | Cure (only in case of infection) |
| M8 | Mount Lebanon | Ciprofloxacin, doxycycline, gentamicin, trimethoprim/sulfamethoxazole | 10 | Prevention and cure |
| M9 | Mount Lebanon | Ciprofloxacin, doxycycline, gentamicin, trimethoprim/sulfamethoxazole | 10 | Prevention and cure |
| N1 | Nabatieh | Amoxicillin, colistin, doxycycline, enrofloxacin, gentamicin, tilmicosin, trimethoprim/sulfamethoxazole | 10 | Prevention and cure |
| N2 | Nabatieh | Amoxicillin, colistin, doxycycline, enrofloxacin, gentamicin, tilmicosin, trimethoprim/sulfamethoxazole | 10 | Prevention and cure |
| N3 | Nabatieh | Amoxicillin, colistin, doxycycline, enrofloxacin, gentamicin, tilmicosin, trimethoprim/sulfamethoxazole | 15 | Prevention and cure |
| ND1 | North | Cephalexin, doxycycline, gentamicin | 3 | Prevention and cure |
| ND2 | North | Cephalexin, doxycycline, gentamicin | 3 | Prevention and cure |
| ND3 | North | Cephalexin, doxycycline, gentamicin | 3 | Prevention and cure |
| ND4 | North | Ciprofloxacin | 3 | Prevention and cure |
| ND5 | North | Doxycycline | 5 | Prevention and cure |
| ND6 | North | Doxycycline | 5 | Prevention and cure |
| ND7 | North | Doxycycline | 5 | Prevention and cure |
| ND8 | North | Ciprofloxacin, colistin, doxycycline, gentamicin | 6 | Prevention and cure |
| ND9 | North | Ciprofloxacin, colistin, doxycycline, gentamicin, trimethoprim/sulfamethoxazole | 10 | Prevention and cure |
| ND10 | North | Ciprofloxacin, colistin, doxycycline, gentamicin, tilmicosin | 6 | Prevention and cure |
| S1 | South | Amoxicillin, colistin | 10 | Prevention and cure |
| S2 | South | Amoxicillin, colistin | 10 | Prevention and cure |
| S3 | South | Amoxicillin, colistin, tilmicosin | 30 | Prevention and cure |
| S4 | South | Amoxicillin, colistin, erythromycin, neomycin | 15 | Prevention and cure |
| S5 | South | Amoxicillin, colistin, erythromycin, neomycin | 15 | Prevention and cure |
| S6 | South | Amoxicillin, colistin, erythromycin, neomycin | 15 | Prevention and cure |
| S7 | South | Colistin, enrofloxacin, gentamicin, sulfadiazine, trimethoprim/sulfamethoxazole | 15 | Prevention and cure |
| S8 | South | Amoxicillin, colistin, doxycycline, gentamicin | 10 | Prevention and cure |
| S9 | South | NA | NA | Cure (only in case of infection) |
| S10 | South | Amoxicillin, colistin, tylosin | 30 | Prevention and cure |
| S11 | South | Doxycycline, gentamicin | 20 | Prevention and cure |
| S12 | South | Amoxicillin, cefpodoxime, ciprofloxacin, colistin, doxycycline, gentamicin, spiramycin, tylosin | 12 | Prevention and cure |
| S13 | South | Amoxicillin, cefpodoxime, ciprofloxacin, colistin, doxycycline, gentamicin, spiramycin, tylosin | 25 | Prevention and cure |
| S14 | South | NA | NA | Cure (only in case of infection) |
| S15 | South | NA | NA | Cure (only in case of infection) |
| S16 | South | Amoxicillin, cefpodoxime, ciprofloxacin, colistin, doxycycline, gentamicin, spiramycin, tylosin | 15 | Prevention and cure |
N = 56.
Farms in which no ESC-resistant strains were isolated.
No antibiotic administration on the sampled flock.
FIG 1Antimicrobial treatment incidence in broiler farms for each administrative region in Lebanon. Antimicrobial usage was quantified using the number of active substances administered multiplied by treatment duration (days) divided by the number of farms as a proxy of treatment incidence for a region. The administrative regions are colored according to their treatment incidence value. Yellow circles represent farm locations.
Proportion of resistance among the 323 ESC-resistant Enterobacterales isolates
| Antibiotics | ||||
|---|---|---|---|---|
| Amoxicillin-clavulanate | 253 (88.8%) | 26 (93.1%) | 7 (100%) | 3 (60%) |
| Cefoxitin | 117 (41.1%) | 7 (25%) | 0 (0%) | 0 (0%) |
| Cefotaxime | 283 (100%) | 28 (100%) | 7 (100%) | 5 (100%) |
| Ceftazidime | 273 (95.8%) | 26 (93.1%) | 7 (100%) | 3 (60%) |
| Cefepime | 201 (70.5%) | 23 (79.3%) | 6 (85.7%) | 3 (60%) |
| Aztreonam | 239 (83.9%) | 23 (79.3%) | 7 (100%) | 3 (60%) |
| Imipenem | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Ertapenem | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gentamicin | 266 (93.3%) | 28 (100%) | 3 (42.8%) | 5 (100%) |
| Ciprofloxacin | 280 (98.2%) | 28 (100%) | 7 (100%) | 5 (100%) |
| Trimethoprim Sulfamethoxazole | 253 (88.8%) | 28 (100%) | 7 (100%) | 5 (100%) |
| Tetracyclines | 283 (100%) | 28 (100%) | 7 (100%) | 5 (100%) |
| Amikacin | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
FIG 2Susceptibility profiles of 323 ESC-resistant Enterobacterales isolates and phenotypic ESBL/AmpC detection. AMC, amoxicillin-clavulanate; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; IMP, imipenem; ETP, ertapenem; ATM, aztreonam; GEN, gentamicin; AMK, amikacin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline.
FIG 3Phylogenetic relationships between the 102 sequenced ESC-resistant E. coli strains. The tree was inferred from the 176,818 SNPs present in genomic regions shared by all isolates. Local branching support values are based on the Shimodaira-Hasegawa test. Values of 1, indicating maximum support, are not displayed. The tree was rooted according to the known relationships between E. coli phylogroups. For each strain, the sequence type, serotype, identifier, region, and farm of origin are indicated in columns 1 to 5 on the right side of the tree. Presence of blaCMY-2, blaESBL genes, mcr-1, and qnr resistance genes detected using ResFinder 2.1 are indicated with a filled box. The strain identifier code includes the region initial followed by a unique sampled animal number per region, the abbreviation of the selection antibiotic, and an isolate number if needed (e.g., S10CTX: isolate selected on cefotaxim from animal number 10 in the region South).
FIG 4Regional distribution of blaCMY-2 and the main ESBL genes and their cooccurrence with the mobile colistin resistance gene mcr-1. In this figure, the Lebanese territory was divided into 3 geographical areas based on (i) similar sampled farm numbers (i.e., the North: North, Akkar, and Baalbeck administrative districts [20 farms]; the center: Mount Lebanon and Beqaa [17 farms]; and the South: South and Nabatieh [19 farms]) and on (ii) the distribution area of the major suppliers of 1-day-old chicks in Lebanon. Diagrams are based on ESBL/AmpC/mcr-1 detection in the 102 E. coli draft genomes of this study. Diagrams of main ESBLs represent the subset of E. coli isolates carrying ESBLs alone or ESBLs and pAmpC CMY-2. Diagrams of mcr-1-positive isolates are based on all ESC-resistant E. coli for each region.